Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision

Summary

Summit has filed ivonescimab for FDA approval in NSCLC and is presenting longer-term clinical data for the candidate. No FDA decision date or trial outcome details are provided in the article.